IQVIA (NYSE:IQV) Cut to “Hold” at Wall Street Zen

by · The Markets Daily

Wall Street Zen downgraded shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a hold rating in a report issued on Saturday morning.

Other research analysts have also recently issued research reports about the stock. BMO Capital Markets initiated coverage on shares of IQVIA in a research report on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective for the company. UBS Group boosted their target price on IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Barclays set a $230.00 price target on IQVIA in a research note on Monday, December 15th. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Finally, Mizuho set a $266.00 target price on shares of IQVIA in a research report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $249.19.

View Our Latest Report on IQV

IQVIA Price Performance

Shares of IQV stock opened at $238.03 on Friday. IQVIA has a 52 week low of $134.65 and a 52 week high of $247.04. The stock has a market capitalization of $40.54 billion, a PE ratio of 32.65, a PEG ratio of 2.42 and a beta of 1.36. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock’s fifty day moving average is $227.80 and its 200-day moving average is $204.13.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC boosted its position in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IQVIA during the second quarter valued at $514,000. Swedbank AB grew its position in shares of IQVIA by 6.5% during the second quarter. Swedbank AB now owns 92,551 shares of the medical research company’s stock worth $14,585,000 after acquiring an additional 5,669 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of IQVIA by 53.0% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 20,289 shares of the medical research company’s stock worth $3,332,000 after acquiring an additional 7,030 shares during the period. 89.62% of the stock is owned by institutional investors.

About IQVIA

(Get Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Recommended Stories